Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis.

What Was Tested

This randomized controlled trial looks at Vitamin D and Calcium in the context of hyperparathyroidism.

Secondary hyperparathyroidism develops early in patients with chronic kidney disease (CKD).

This phase 2 study evaluated the effects of the oral calcimimetic cinacalcet hydrochloride in patients with CKD not on dialysis therapy.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Vitamin D and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D.

Some participants received a placebo instead of Vitamin D, giving a reference point.

What Was Measured

Secondary hyperparathyroidism develops early in patients with chronic kidney disease (CKD).

This phase 2 study evaluated the effects of the oral calcimimetic cinacalcet hydrochloride in patients with CKD not on dialysis therapy.

Topics PubMed links to this paper include Calcium, Chronic Disease, Cinacalcet, Hyperparathyroidism, Secondary, Kidney Diseases, Naphthalenes and Parathyroid Hormone.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D and Calcium in people with hyperparathyroidism.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2005 (American journal of kidney diseases : the official journal of the National Kidney Foundation), a journal based in United States.

More context: the related Vitamin D, K2, Magnesium and Zinc library page, Hyperparathyroidism research.